View Item 

Show simple item record

Characterization of the anti‐factor VIII immunoglobulin profile in patients with hemophilia A by use of a fluorescence‐based immunoassay
dc.contributor.authorBoylan, B.en_US
dc.contributor.authorRice, A. S.en_US
dc.contributor.authorDunn, A. L.en_US
dc.contributor.authorTarantino, M. D.en_US
dc.contributor.authorBrettler, D. B.en_US
dc.contributor.authorBarrett, J. C.en_US
dc.contributor.authorMiller, C. H.en_US
dc.date.accessioned2015-02-19T15:40:12Z
dc.date.available2016-03-02T19:36:56Zen
dc.date.issued2015-01en_US
dc.identifier.citationBoylan, B.; Rice, A. S.; Dunn, A. L.; Tarantino, M. D.; Brettler, D. B.; Barrett, J. C.; Miller, C. H. (2015). "Characterization of the anti‐factor VIII immunoglobulin profile in patients with hemophilia A by use of a fluorescence‐based immunoassay." Journal of Thrombosis and Haemostasis (1): 47-53.en_US
dc.identifier.issn1538-7933en_US
dc.identifier.issn1538-7836en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/110532
dc.publisherWiley Periodicals, Inc.en_US
dc.subject.otherfactor VIIIen_US
dc.subject.otherhemophilia Aen_US
dc.subject.otherimmunoassayen_US
dc.subject.otherinherited blood coagulation disordersen_US
dc.subject.otherfactor VIII deficiencyen_US
dc.titleCharacterization of the anti‐factor VIII immunoglobulin profile in patients with hemophilia A by use of a fluorescence‐based immunoassayen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelInternal Medicine and Specialtiesen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/110532/1/jth12768.pdf
dc.identifier.doi10.1111/jth.12768en_US
dc.identifier.sourceJournal of Thrombosis and Haemostasisen_US
dc.identifier.citedreferenceSoucie JM, Miller CH, Kelly FM, Payne AB, Creary M, Bockenstedt PL, Kempton CL, Manco‐Johnson MJ, Neff AT. A study of prospective surveillance for inhibitors among persons with haemophilia in the United States. Haemophilia 2014; 20: 230 – 7.en_US
dc.identifier.citedreferenceGuh S, Grosse SD, McAlister S, Kessler CM, Soucie JM. Healthcare expenditures for males with haemophilia and employer‐sponsored insurance in the United States, 2008. Haemophilia 2012; 18: 268 – 75.en_US
dc.identifier.citedreferenceKasper CK, Aledort L, Aronson D, Counts R, Edson JR, van Eys J, Fratantoni J, Green D, Hampton J, Hilgartner M, Levine P, Lazerson J, McMillan C, Penner J, Shapiro S, Shulman NR. Proceedings: a more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975; 34: 612.en_US
dc.identifier.citedreferenceVerbruggen B, Novakova I, Wessels H, Boezeman J, van den Berg M, Mauser‐Bunschoten E. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost 1995; 73: 247 – 51.en_US
dc.identifier.citedreferenceBlanco AN, Alcira PA, Grosso SH, Gennari LC, Perez BR, Lazzari MA. A chromogenic substrate method for detecting and titrating anti‐factor VIII antibodies in the presence of lupus anticoagulant. Haematologica 2002; 87: 271 – 8.en_US
dc.identifier.citedreferenceGilles JG, Arnout J, Vermylen J, Saint‐Remy JM. Anti‐factor VIII antibodies of hemophiliac patients are frequently directed towards nonfunctional determinants and do not exhibit isotypic restriction. Blood 1993; 82: 2452 – 61.en_US
dc.identifier.citedreferenceWhelan SF, Hofbauer CJ, Horling FM, Allacher P, Wolfsegger MJ, Oldenburg J, Male C, Windyga J, Tiede A, Schwarz HP, Scheiflinger F, Reipert BM. Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients. Blood 2013; 121: 1039 – 48.en_US
dc.identifier.citedreferenceLewis KB, Hughes RJ, Epstein MS, Josephson NC, Kempton CL, Kessler CM, Key NS, Howard TE, Kruse‐Jarres R, Lusher JM, Walsh CE, Watts RG, Ettinger RA, Pratt KP. Phenotypes of allo‐ and autoimmune antibody responses to FVIII characterized by surface plasmon resonance. PLoS ONE 2013; 8: e61120.en_US
dc.identifier.citedreferenceNguyen PC, Lewis KB, Ettinger RA, Schuman JT, Lin JC, Healey JF, Meeks SL, Lollar P, Pratt KP. High‐resolution mapping of epitopes on the C2 domain of factor VIII by analysis of point mutants using surface plasmon resonance. Blood 2014; 123: 2732 – 9.en_US
dc.identifier.citedreferenceLavigne‐Lissalde G, Tarrade C, Lapalud P, Chtourou S, Schved JF, Granier C, Villard‐Saussine S. Simultaneous detection and epitope mapping of anti‐factor VIII antibodies. Thromb Haemost 2008; 99: 1090 – 6.en_US
dc.identifier.citedreferenceKrudysz‐Amblo J, Parhami‐Seren B, Butenas S, Brummel‐Ziedins KE, Gomperts ED, Rivard GE, Mann KG. Quantitation of anti‐factor VIII antibodies in human plasma. Blood 2009; 113: 2587 – 94.en_US
dc.identifier.citedreferenceZakarija A, Harris S, Rademaker AW, Brewer J, Krudysz‐Amblo J, Butenas S, Mann KG, Green D. Alloantibodies to factor VIII in haemophilia. Haemophilia 2011; 17: 636 – 40.en_US
dc.identifier.citedreferenceMiller CH, Rice AS, Boylan B, Shapiro AD, Lentz SR, Wicklund BM, Kelly FM, Soucie JM. Comparison of clot‐based, chromogenic and fluorescence assays for measurement of factor VIII inhibitors in the US Hemophilia Inhibitor Research Study. J Thromb Haemost 2013; 11: 1300 – 9.en_US
dc.identifier.citedreferenceLebreton A, Lapalud P, Chambost H, Biron‐Andreani C, Morange PE, Combescure C, Marques‐Verdier A, Berger C, Schved JF, Granier C, Lavigne‐Lissalde G. Prevalence and epitope specificity of non‐neutralising antibodies in a large cohort of haemophilia A patients without inhibitors. Thromb Haemost 2011; 105: 954 – 61.en_US
dc.identifier.citedreferenceTowfighi F, Gharagozlou S, Sharifian RA, Kazemnejad A, Esmailzadeh K, Managhchi MR, Shokri F. Comparative measurement of anti‐factor VIII antibody by Bethesda assay and ELISA reveals restricted isotype profile and epitope specificity. Acta Haematol 2005; 114: 84 – 90.en_US
dc.identifier.citedreferencevan Helden PM, van den Berg HM, Gouw SC, Kaijen PH, Zuurveld MG, Mauser‐Bunschoten EP, Aalberse RC, Vidarsson G, Voorberg J. IgG subclasses of anti‐FVIII antibodies during immune tolerance induction in patients with hemophilia A. Br J Haematol 2008; 142: 644 – 52.en_US
dc.identifier.citedreferenceMiller CH, Platt SJ, Rice AS, Kelly F, Soucie JM. Validation of Nijmegen‐Bethesda assay modifications to allow inhibitor measurement during replacement therapy and facilitate inhibitor surveillance. J Thromb Haemost 2012; 10: 1055 – 61.en_US
dc.identifier.citedreferenceKlintman J, Hillarp A, Berntorp E, Astermark J. Long‐term anti‐FVIII antibody response in Bethesda‐negative haemophilia A patients receiving continuous replacement therapy. Br J Haematol 2013; 163: 385 – 92.en_US
dc.identifier.citedreferenceLing M, Duncan EM, Rodgers SE, Street AM, Lloyd JV. Low detection rate of antibodies to non‐functional epitopes on factor VIII in patients with hemophilia A and negative for inhibitors by Bethesda assay. J Thromb Haemost 2003; 1: 2548 – 53.en_US
dc.identifier.citedreferenceHay CR, Ollier W, Pepper L, Cumming A, Keeney S, Goodeve AC, Colvin BT, Hill FG, Preston FE, Peake IR. HLA class II profile: a weak determinant of factor VIII inhibitor development in severe haemophilia A. UKHCDO Inhibitor Working Party. Thromb Haemost 1997; 77: 234 – 7.en_US
dc.identifier.citedreferenceDe Barros MF, Herrero JC, Sell AM, De Melo FC, Braga MA, Pelissari CB, Machado J, De Souza SS, De Souza HL, Visentainer JE. Influence of class I and II HLA alleles on inhibitor development in severe haemophilia A patients from the south of Brazil. Haemophilia 2012; 18: e236 – 40.en_US
dc.identifier.citedreferenceAstermark J, Oldenburg J, Pavlova A, Berntorp E, Lefvert AK. Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A. Blood 2006; 107: 3167 – 72.en_US
dc.identifier.citedreferencePavlova A, Delev D, Lacroix‐Desmazes S, Schwaab R, Mende M, Fimmers R, Astermark J, Oldenburg J. Impact of polymorphisms of the major histocompatibility complex class II, interleukin‐10, tumor necrosis factor‐alpha and cytotoxic T‐lymphocyte antigen‐4 genes on inhibitor development in severe hemophilia A. J Thromb Haemost 2009; 7: 2006 – 15.en_US
dc.identifier.citedreferenceAstermark J, Oldenburg J, Carlson J, Pavlova A, Kavakli K, Berntorp E, Lefvert AK. Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A. Blood 2006; 108: 3739 – 45.en_US
dc.identifier.citedreferenceKempton CL, Soucie JM, Abshire TC. Incidence of inhibitors in a cohort of 838 males with hemophilia A previously treated with factor VIII concentrates. J Thromb Haemost 2006; 4: 2576 – 81.en_US
dc.identifier.citedreferenceKruse‐Jarres R. Inhibitors: our greatest challenge. Can we minimize the incidence? Haemophilia 2013; 19 ( Suppl. 1 ): 2 – 7.en_US
dc.identifier.citedreferenceLeissinger CA. Prevention of bleeds in hemophilia patients with inhibitors: emerging data and clinical direction. Am J Hematol 2004; 77: 187 – 93.en_US
dc.identifier.citedreferenceWaters B, Lillicrap D. The molecular mechanisms of immunomodulation and tolerance induction to factor VIII. J Thromb Haemost 2009; 7: 1446 – 56.en_US
dc.identifier.citedreferenceDiMichele DM. Immune tolerance in haemophilia: the long journey to the fork in the road. Br J Haematol 2012; 159: 123 – 34.en_US
dc.identifier.citedreferenceColowick AB, Bohn RL, Avorn J, Ewenstein BM. Immune tolerance induction in hemophilia patients with inhibitors: costly can be cheaper. Blood 2000; 96: 1698 – 702.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
jth12768.pdf
Size:
191.4KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.